Skip to content

MCK changes

Pick any two versions below to diff them.

View the full Nov 21, 2026 version
Price
$1060.84 → $1069.43(+0.8%)
About
McKesson distributes prescription drugs and medical supplies, and it sells services to drug makers, pharmacies and care providers, mostly in the United States and Canada. It has four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions and Medical-Surgical Solutions. In Q2 fiscal 2027, which ended on September 30, 2026, revenue was $111.0 billion. North American Pharmaceutical had revenue of $91.4 billion, Oncology & Multispecialty $15.0 billion, Medical-Surgical Solutions $3.1 billion and Prescription Technology Solutions $1.5 billion. added: GLP-1 drugs, the class of weight-loss and diabetes drugs, brought about $16 billion of revenue in Q2 fiscal 2027, about 14% of company revenue, up 26% from a year earlier. McKesson reports that revenue in North American Pharmaceutical, so it is not part of the $1.5 billion of Prescription Technology Solutions. That segment sells access services, such as prior authorization, and third-party logistics. Management says its services grow for GLP-1 and non-GLP-1 drugs, but the company does not say what share of the segment's revenue or profit comes from GLP-1 drugs. Revenue was $403.4 billion in fiscal 2026. Its fiscal year ends on March 31. Funds managed by affiliates of Apollo own about 13% of Medical-Surgical Solutions, and McKesson plans to separate that business into an independent company. The company is based in Irving, Texas, and its shares trade on the New York Stock Exchange.
Thesis
McKesson trades at a premium because investors pay for steady growth in a business with few rivals. Adjusted EPS rose 18% to $39.11 in fiscal 2026, and the company now expects $45.60 to $46.40 for fiscal 2027, a growth of 17% to 19%. Three large distributors deliver most prescription drugs in the United States, and McKesson extended its distribution agreement with CVS Health through June 2032. Buybacks also lift EPS: diluted shares fell 6% in a year to 116.7 million in Q2 fiscal 2027. added: In oncology, McKesson works with practices through a management service organization (MSO): an MSO runs the business side of a medical practice, such as purchasing, billing, technology and group purchasing, and the doctors keep the care. The U.S. Oncology Network, which McKesson says serves over 3,400 providers, works this way. The flywheel is simple: a practice that joins the network buys its specialty drugs through McKesson, so each new practice adds distribution volume, and group purchasing, research and technology services give the practice reasons to stay. McKesson says Oncology & Multispecialty revenue rose 24% in Q2 fiscal 2027 because of specialty distribution and higher volumes across its provider platforms. The company does not say how much distribution volume comes from each new practice. For the premium to be earned, three things must be true. Adjusted EPS must keep growing at or above the long-term target of 13% to 16% a year as oncology and biopharma services grow. The company must separate Medical-Surgical Solutions, integrate Precision Medicine Group and close the Option Care Health investment, which it expects in the first half of 2027, without large new charges. The opioid liability of $5.2 billion, paid out through 2038, and the class actions after the August 2026 cybersecurity incident must not grow into larger costs. The Q3 fiscal 2027 report, expected in early February 2027, gives the next test, and the fiscal 2028 guidance in May 2027 gives a larger one. If EPS growth slows toward the growth of drug volumes, the premium can shrink over the next two years.
Risks
The stock price expects EPS growth of 13% or more each year for many years. A slower year, a lost large customer or lower profit on branded drugs can lower the multiple that investors pay. McKesson had an estimated opioid litigation liability of $5.2 billion at September 30, 2026, mostly paid through 2038. Some local governments and private plaintiffs are not part of the settlements, and new rulings can add costs. The company is separating Medical-Surgical Solutions, integrating Precision Medicine Group and investing in Option Care Health at the same time. Delays, charges or weak results from these deals can lower returns. After the cybersecurity incident of August 2026, class actions allege that the company did not protect health and personal data. Settlements or new rules on data protection can add costs. U.S. drug pricing rules can change the profit that distributors earn on branded and generic drugs. added: Two federal programs can lower what Medicare pays for cancer drugs given in a doctor's office (Medicare Part B). McKesson's Oncology & Multispecialty segment, with revenue of $15.0 billion in Q2 fiscal 2027, sells these drugs and supports the practices that give them. The first is the Medicare drug price negotiation of the Inflation Reduction Act: its first cycle that includes Part B drugs sets maximum fair prices that take effect on January 1, 2028. The second is the GLOBE model of the CMS Innovation Center (CMMI), a mandatory Part B model with most-favored-nation pricing. CMS published its final rule on September 30, 2026, and the model starts on January 1, 2027 with the collection of international price data. The rule did not exclude cancer drugs. Law firm summaries say drug makers owe the rebates, not distributors, and that CMS projects savings of only $440 million over seven years. McKesson did not name either program on its Q2 fiscal 2027 call and gave no estimate of the effect on its profit. Lower prices can cut the dollar value of drug purchases that the segment handles, and they can press the margins of the practices it supports. These notes are not a forecast.